About ADVANTIGEN BIOSCIENCES LLC
AdvantiGen Biosciences is developing next-generation immunotherapies by targeting Siglec-5 on activated T-cells for cancer treatment. The company leverages expertise in monoclonal antibodies and NIRID™ technology to create advanced therapeutics and biomarkers for patient selection and stratification.
Development of next-generation immunotherapiesExpertise in monoclonal antibodies (mAbs)NIRID™ (Near InfraRed Identification and Detection) technologyComplementary biomarker developmentPre-clinical and clinical patient selection and stratification
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ADVANTIGEN BIOSCIENCES LLC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.